BioSpace News Archive

Exicure, Inc., the pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid constructs, announced the dosing of the first patient enrolled in the Phase 2 dose expansion stage of the cavrotolimod Phase 1b/2 clinical trial.

Sigilon Therapeutics, Inc., a biotechnology company developing functional cures for patients with chronic diseases through its Shielded Living Therapeutics™ platform, today announced the appointment of Kavita Patel, M.D., to its Board of Directors. Dr. Patel, a practicing physician, has been a leading voice in health policy development and patient-centered care and delivery systems. “As a recognized leader in cutti

Humanigen, Inc., a clinical stage biopharmaceutical company focused on preventing and treating cytokine storm with lenzilumab, the company’s proprietary Humaneered® anti-human granulocyte macrophage-colony stimulating factor monoclonal antibody, announced additional analysis on the first clinical use of lenzilumab in 12 COVID-19 patients.

Pharm-Olam, LLC, a global, midsized CRO offering full-service clinical development solutions to the pharmaceutical and biotech industry, is launching Protocol Optimization Services to support the study development needs of their biopharma clients.

Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), a clinical stage pharmaceutical company with a broad portfolio of drug candidates, today announced that a repeat of previous in vitro testing has corroborated the antiviral potential of WP1122.

MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced the appointment of Stephen Eck, M.D., Ph.D. as Senior Vice President, Clinical Development & Chief Medical Officer, effective beginning July 1, 2020. “We are excited to announce the addition of Stephen Eck to the MacroGenics leaders

Cascade Chemistry, a leading contract research and manufacturing organization serving the pharmaceutical, materials, and chemical industries, today announced that it has been selected to produce the active pharmaceutical ingredient (API) for clinical trial supplies of RBT-9, an investigational therapy entering a Phase 2 trial for the treatment of COVID-19 patients who are at high risk of deteriorating health due to age or comorbid conditions such as kidney or cardiovascular disease.

Inozyme Pharma, Inc., a rare disease biopharmaceutical company developing novel therapeutics for the treatment of disorders of abnormal mineralization, announced today the appointment of Doug Treco, Ph.D., as Chairman of the Company’s Board of Directors

International Osteoporosis Foundation Announces First-of-its-kind Partnership With University of Oxford, Amgen and UCB to Combat Global Public Health Burden of Osteoporosis

Stevanato Group, SCHOTT, and Gerresheimer confirm the readiness to support future COVID-19 Vaccine with pharmaceutical containers